Together, these results demonstrate that the loss of LCMT1/decreased PP2A-C α-carboxymethylation is a major determinant of AR-addicted PCa and supports the therapeutic use of AR degraders and selective small molecule modulators of PP2A for refractory prostate cancer treatment. This evidence concerns the gene LCMT1 and prostate cancer.